Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 221Colorectal Neoplasms 196Rectal Neoplasms 174Stomach Neoplasms 116Pancreatic Neoplasms 100Neoplasm Metastasis 77Colonic Neoplasms 59Neoplasms 50Esophageal Neoplasms 39Triple Negative Breast Neoplasms 38Nasopharyngeal Carcinoma 28Biliary Tract Neoplasms 27Cholangiocarcinoma 22Gallbladder Neoplasms 20Locally Advanced Rectal Cancer 17Carcinoma, Hepatocellular 17Adenocarcinoma 15Gastrointestinal Neoplasms 13Colorectal Cancer Metastatic 13Head and Neck Neoplasms 12Bile Duct Neoplasms 12Adenocarcinoma Of Esophagus 12Esophageal Squamous Cell Carcinoma 11Breast Neoplasms, Male 11Brain Neoplasms 11Liver Neoplasms 10Carcinoma, Renal Cell 10Neuroendocrine Tumors 9Unspecified Adult Solid Tumor, Protocol Specific 8Squamous Cell Carcinoma of Head and Neck 8

Interventions

Trastuzumab 19pyrotinib 14pertuzumab 8Docetaxel 7Paclitaxel 6Capecitabine 4Carboplatin 3neratinib 2Protons 2Neoadjuvant Therapy 2Fulvestrant 2Ado-Trastuzumab Emtansine 2tucatinib 1trastuzumab deruxtecan 1pegfilgrastim 1palbociclib 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1atezolizumab 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Goserelin 1Genetic Testing 1Fluorodeoxyglucose F18 1Enfuvirtide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × HER2-positive Breast Cancer × Capecitabine × Clear all
NCT07166367 2025-09-10

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

National Cancer Centre, Singapore

Phase 2 Terminated
3 enrolled
Breast

HER2-positive Breast Cancer

NCT06992882 2025-07-18

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

Fudan University

Phase 3 Recruiting
2,306 enrolled
Breast

HER2-positive Breast Cancer

NCT06217185 2024-02-28

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Hebei Medical University Fourth Hospital

Phase 4 Recruiting
100 enrolled
Breast

HER2-positive Breast Cancer

NCT03684863 2018-09-26

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Shandong Cancer Hospital and Institute

Phase 2 Unknown
200 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡